Skip to main navigation Skip to search Skip to main content

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

  • Austin G. Kulasekararaj
  • , Antonio M. Risitano
  • , Jaroslaw P. Maciejewski
  • , Rosario Notaro
  • , Peter Browett
  • , Jong Wook Lee
  • , Mingjun Huang
  • , Michael Geffner
  • , Robert A. Brodsky
  • King's College Hospital NHS Foundation Trust
  • King's College London
  • University of Naples Federico II
  • AORN Moscati
  • Cleveland Clinic Foundation
  • Azienda Ospedaliera Careggi
  • la Prevenzione e la Rete Oncologica
  • The University of Auckland
  • Alexion Pharmaceuticals, Inc.
  • Inc.
  • Johns Hopkins University

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science